Nanexa more than doubles on Novo Nordisk injectables deal
Shares in Nanexa (NANEXA) more than doubled in early trading last month after the Swedish drug-delivery company signed a global licensing agreement with Novo Nordisk (NVO) worth up to about €1.17bn ($1.33bn).
